FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer

Li,Li; Zhang,Sufang; Wei,Lei; Wang,Zhongfu; Ma,Wei; Liu,Fangying; Qian,Yechang

doi:10.3892/ol.2018.8903

FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer

Authors:
- Li Li
- Sufang Zhang
- Lei Wei
- Zhongfu Wang
- Wei Ma
- Fangying Liu
- Yechang Qian
View Affiliations

Affiliations: Department of Respiratory Disease, Baoshan Branch, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201900, P.R. China, Department of Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200082, P.R. China
Published online on: June 5, 2018 https://doi.org/10.3892/ol.2018.8903
Pages: 2490-2494
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the expression of FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis (IPF) and lung cancer (LC) as well as their clinical significance. Reverse transcription-quantitative PCR (RT-qPCR) and western blotting were used to detect FGF2 and FGFR2 expression in LC and adjacent normal tissues of LC patients and lavage fluid of idiopathic pulmonary fibers patients and normal controls (confirmed by bronchoalveolar lavage examination). The expression levels of FGF2 mRNA and protein in the non-small cell LC tissues were significantly higher than those in the adjacent normal tissues (P<0.001). The expression level of FGF2 protein in lavage fluid of patients with IPF was higher than that of the control group (P<0.001). The expression level of FGFR2 mRNA in the non‑small cell LC tissues was significantly higher than that in the adjacent normal tissues (P<0.001). The expression level of FGFR2 protein in the non-small cell LC tissues was higher than that in the adjacent normal lung tissues (P<0.001). The expression levels of FGF2 mRNA and FGFR2 mRNA in cancer tissues were not significantly correlated with age, sex and history of smoking (P>0.05), but were significantly correlated with lymph node metastasis, tumor differentiation and TNM staging. FGF2 and FGFR2 proteins were highly expressed in cancer tissues of LC patients and lavage fluid of patients with IPF. The expression of FGF2 mRNA and FGFR2 mRNA was correlated with lymph node metastasis and TNM stage. The high expression levels of FGF2 mRNA and FGFR2 mRNA were associated with tumor metastasis and poor prognosis of LC patients.

View Figures

View References

1	Zhang Y, Wei X and Pan T: Simultaneous surgical treatment of non-small cell lung cancer and off-pump coronary artery bypass grafting. Zhongguo Fei Ai Za Zhi. 12:332–336. 2009.(In Chinese). PubMed/NCBI
2	Sheffield BS, Fulton R, Kalloger SE, Milne K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E, et al: Investigation of PD-L1 biomarker testing methods for PD-1 axis inhibition in non-squamous non-small cell lung cancer. J Histochem Cytochem. 64:587–600. 2016. View Article : Google Scholar : PubMed/NCBI
3	Sorber L, Zwaenepoel K, Deschoolmeester V, van Schil PE, van Meerbeeck J, Lardon F, Rolfo C and Pauwels P: Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 107:100–107. 2017. View Article : Google Scholar : PubMed/NCBI
4	Zhang X, Liu Y, Shao H and Zheng X: Obesity paradox in lung cancer prognosis: Evolving biological insights and clinical implications. J Thorac Oncol. 12:1478–1488. 2017. View Article : Google Scholar : PubMed/NCBI
5	Richeldi L, Collard HR and Jones MG: Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952. 2017. View Article : Google Scholar : PubMed/NCBI
6	Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, et al: Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: A randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 5:22–32. 2017. View Article : Google Scholar : PubMed/NCBI
7	Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R and Hansell DM: Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 195:78–85. 2017. View Article : Google Scholar : PubMed/NCBI
8	Morrissey C, Corey E, Brown L, Coleman I, Nguyen H, Schweizer M and Nelson P: Targeting the FGFR pathway in androgen receptor negative castration resistant prostate cancer. Cancer Res. 77:Abst 2076. 2017.doi:10.1158/1538-7445.AM2017-2076. View Article : Google Scholar : PubMed/NCBI
9	Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and survival in lung cancer. Lung Cancer. 86:78–84. 2014. View Article : Google Scholar : PubMed/NCBI
10	Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr and Raghu G; Idiopathic Pulmonary Fibrosis Clinical Research Network: Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 370:2093–2101. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hutchinson J: Idiopathic pulmonary fibrosis: Another step in understanding the burden of this disease. Eur Respir J. 48:26–28. 2016. View Article : Google Scholar : PubMed/NCBI
12	Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 60:598–609. 2014. View Article : Google Scholar : PubMed/NCBI
13	Katoh M and Nakagama H: FGF receptors: Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014. View Article : Google Scholar : PubMed/NCBI
14	Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, et al: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7:252–263. 2017. View Article : Google Scholar : PubMed/NCBI
15	Li D, Zhang H, Ma L, Han Y, Xu M, Wang Z, Jiang H, Zhang W, Wang L and Pan Y: Associations between microRNA binding site SNPs in FGFs and FGFRs and the risk of non-syndromic orofacial cleft. Sci Rep. 6:310542016. View Article : Google Scholar : PubMed/NCBI
16	Soulitzis N, Karyotis I, Delakas D and Spandidos DA: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
17	Siegfried JM, Farooqui M, Rothenberger NJ, Dacic S and Stabile LP: Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. Oncotarget. 8:24063–24076. 2017. View Article : Google Scholar : PubMed/NCBI
18	Babina IS and Turner NC: Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 17:318–332. 2017. View Article : Google Scholar : PubMed/NCBI
19	Mori Y, Nakamura S, Kishimoto S, Kawakami M, Suzuki S, Matsui T and Ishihara M: Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier. Int J Nanomed. 5:147–155. 2010. View Article : Google Scholar
20	Hasday JD, Scheraga RG, Thompson C, Tulapurkar M, Cowan MJ, Sun JF, Cai RM, Logun C, Todd NW, Shelhamer J, et al: Heat-Shock accelerates human lung epithelial wound healing by activating expression of fibroblast growth factor (FGF)-1: Implications for idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 193:A14612016.